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for many cancer types, but consistently only a limited 
subset of patients. especially in cancer types with high 
mutation rates, e.g. melanoma, non-small cell lung can-
cer and renal cancer, showed effective responses to im-
munotherapeutic approaches. in addition to high costs 
and serious toxicity profiles, the lack of tools to measure 
the behavior of immune cell populations hampers effi-
cient application of immune therapy.
With respect to immunotherapy, immune cell popula-
tions such as cytotoxic cd8+ T-cells, cd56+ nK cells 
and myeloid phagocytic cells play decisive roles, exem-
plified in immune checkpoint inhibitor therapy. Target-
dynamic and reciprocal interactions between tumor cells and immune cells promote the initiation, pro-
gression, metastasis and therapy-resistance of cancer. 
Distinct patterns of tumor-infiltrating immune cell pop-
ulations have been demonstrated to impact prognosis 
in most cancer types.1-3 in the past years, several im-
munotherapies have successfully been introduced in the 
clinic aiming to increase the number and activity of tu-
mor-infiltrating immune cells, e.g. immune checkpoint 
inhibitors, adoptive T-cell transfer, chimeric antigen re-
ceptor (car) T-cells and dendritic cell-based (dc) vac-
cines. Spectacular clinical successes have been noted 
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dynamic interactions between tumor cells and immune cells promote the initiation, progression, metastasis and therapy-resistance of cancer. 
With respect to immunotherapy, immune cell populations such as cytotoxic cd8+ T-cells, cd56+ nK cells and myeloid phagocytic cells play 
decisive roles. from an imaging perspective, the immune system displays unique challenges, which have implications for the design and per-
formance of studies. The immune system comprises highly mobile cells that undergo distinct phases of development and activation. These cells 
circulate through several compartments during their active life span and accumulate in rather limited numbers in cancer lesion, where their ef-
fector phenotype further diversifies. Given these features, accurate evaluation of the tumor microenvironment and its cellular components during 
anti-cancer immunotherapy is challenging. In-vivo imaging currently offers quantitative and sensitive modalities that exploit long-lived tracers 
to interrogate, e.g. distinct immune cell populations, metabolic phenotypes, specific targets relevant for therapy or critical for their effector func-
tion. This review provides a comprehensive overview of current status for in-vivo imaging tumor-infiltrating immune cell populations, focusing 
on lymphocytes, nK cells and myeloid phagocytic cells, with emphasis on clinical translation.
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evaluation of the tumor microenvironment and its cellu-
lar components is enormous. In-vivo imaging currently 
offers quantitative and sensitive modalities that exploit 
long-lived tracers to interrogate metabolic phenotypes, 
specific targets relevant for therapy or critical for their 
effector function. This review will highlight these as-
pects of imaging specific immune cell populations in 
cancer lesions.
Modalities for in-vivo immune cell imaging
a diverse range of molecular imaging techniques and 
cell-labeling strategies are available for preclinical and 
clinical studies. Modalities that are currently used in 
clinical settings include positron emission tomography 
(PeT) and single-photon emission computed tomog-
raphy (SPecT) radionuclide imaging, as well as non-
nuclear imaging techniques e.g. magnetic resonance 
(Mr) imaging, ultrasound (uS). in preclinical settings, 
optical imaging techniques, e.g. fluorescence (FLI) and 
bioluminescence (Bli) play an important role, as well 
as photoacoustic (Pa) imaging. The penetration depth 
of the signals derived from these techniques is currently 
too low for detection of labeled immune cells in human 
subjects. The technical properties of these techniques 
are comprehensively reviewed elsewhere.11-14
Current labels for cell labeling
cell labeling can be performed in two ways: direct-
ly and indirectly (figure 1). for direct labeling of the 
target cells, the imaging label is stably attached to or 
entrapped in the cell during in-vitro incubation, as re-
viewed by Wolfs et al.11 Most direct labeling strategies 
involve radionuclide imaging, however nanoparticle-
ing Pd-1/Pd-l1 and cTla4, the presence and function 
of cd8+ T-cells has shown to be a prerequisite for re-
sponse,4-7 perhaps explaining the limited and heteroge-
neous responses observed in clinical trials.
accurate evaluation of a highly dynamic and complex 
process such as anti-cancer immunotherapy, involving 
multiple immune cell populations with multifaceted 
roles, is challenging.8 factors that will need to be con-
sidered include not only the presence and numbers of 
cells, but also intra-tumoral localization, functional ori-
entation and reciprocal interactions. Moreover, as these 
factors vary amongst patients and cancer lesions, het-
erogeneity should be addressed on a whole body scale.9 
Studies that have been able to capture a more compre-
hensive evaluation of cancer cells, immune cell subsets 
and their functional orientations have unquestionably 
led to valuable insights,10 using quantitative multicolor 
immunohistochemistry and gene expression profiling 
of tumor biopsy samples. however, histopathologi-
cal evaluation requires invasive procedures to obtain a 
single sample of one metastasis in a single point in time 
of a patient with a heterogeneous tumor load, and has, 
therefore, limited potential to optimize immunothera-
pies in clinical settings.
In-vivo imaging provides a non-invasive alternative 
for longitudinal evaluation on a whole-body scale, pro-
vided that distincT-cell populations can be assessed si-
multaneously at sufficient sensitivity to detect limited 
numbers of cells per volume.
Implications for in-vivo imaging
from an imaging perspective, the immune system 
displays unique challenges, which have implications 
for the design and performance of such studies. The 
immune system comprises highly mobile cells that un-
dergo distinct phases of development and activation, 
and circulate through several compartments during 
their active life span. in a simplistic view, lymphocytes, 
including cd4+ helper T-cells, cd8+ cytotoxic T-cells 
and cd56+ nK cells can be regarded as relatively short-
lived highly mobile effector cells that proliferate, exe-
cute their effector function and then die. To the contrary, 
macrophages can be referred to as long-lived, less mo-
bile, master regulators of the local immune microenvi-
ronment with highly plastic and reversible phenotypes.
given these features, the complexity of an accurate 










































































































































































































































































































































































































































































































































Zeelen in-ViVo iMaging of TuMor-infilTraTing iMMune cellS
58 The QuarTerly Journal of nuclear Medicine and Molecular iMaging March 2018
Passive diffusion over the cell membrane
Lipophilic agents like oxine, hexamethyl-propylene 
amine oxime (hMPao), pyruvaldehyde-bis-n4-me-
thylthiosemicarbazone (PTSM) and tropolone passively 
diffuse over the cell membrane, complexes fall apart in 
the cytoplasm by reduction and the radionuclide disso-
ciates and binds to intracellular proteins. These tracers 
are amongst the earliest and most widely used tech-
niques for cell labeling.16, 17
Cell labeling with 111In-oxine.—in the mid-
1970’s, 111in-oxine was introduced as a labeling agent 
for leukocytes; in 1995 it was approved for human use. 
although 111in-oxine is routinely used in the clinic for 
labeling of leukocytes for imaging of infection, mes-
enchymal stem cells, hematopoietic stem cells as well 
as cd133+ peripheral blood progenitor cells have been 
labeled, amongst others. The 111in-oxine solution is 
in most countries supplied in a vial as a ready-to-use 
radiopharmaceutical. 111in forms an uncharged pseu-
do-octahedral n3o3 complex with three molecules of 
8-hydroxyquinoline (oxine). The complex is neutral 
and lipophilic, which enables it to penetrate through the 
bilayer cell membrane. given the low stability constant 
of 111in-complexes, cytoplasmic proteins bind 111in and 
the cell releases 8-hydroxyquinoline. immune cell la-
beling with 111In-oxine is in general efficient but some 
studies have reported gradual efflux of 111in from the 
cell (up to >60% after 48 hours).18 a particular con-
cern of 111in-oxine is its direct toxicity. next to high-
energy gamma rays of 171 and 245 keV, 111in also emits 
low energy auger electrons that cause damage to the 
cell.19-21 111in-oxine or 111in-tropolone has shown to im-
pair with the proliferative capacity and affects the cell’s 
chromosomal architecture of cytotoxic T-cells. howev-
er, viability, phenotype and migration of lymphocytes 
was not significantly affected.22, 23
Cell labeling with 99mTc-HMPAO.—hMPao bound 
to 99mTc (99mTc-hMPao) is the most widely used com-
plex for white blood cell labeling 24 and 99mTc-hMPao 
kit preparations have been commercially available 
since 1988. Upon reconstitution of the HMPAO kit 
with 99mTc-pertechnetate from a fresh generator eluate a 
lipophilic complex is formed. The lipophilic complex is 
transformed into free 99mTc-pertechnetate and a hydro-
philic 99mTc-hMPao complex in aqueous solution over 
based cell labeling may also apply to other imaging 
modalities, including Mr, uS, computed tomography 
(cT) and optical imaging.
for indirect labeling of cells, imaging reporter gene 
constructs that encode for receptors or enzymes that 
specifically will entrap the injectable imaging label in 
vivo, are introduced in the target cells.15 These tech-
niques mostly apply to radionuclide imaging and opti-
cal imaging.
Direct labeling strategies
direct cell labeling strategies can require incubation 
of the immune cells with the imaging labeling prior to 
re-infusion. Advantages of this approach are the lack of 
background as the imaging label is in principle not pres-
ent in other host tissues or cells. furthermore, in general 
the radioactive dose administered to the subject is low. 
its labeling procedure is mostly simple and based on 
incubation. lastly, direct labeling does not involve ge-
netic manipulation of the therapeutic cells.
a disadvantage of direct cell labeling is the gradual 
leakage of most labels from the cells and release of the 
label from dying cells. This causes uptake of the label by 
bystander cells or diffusion into the tissue. for ex-vivo 
labeling in clinical studies, particular infrastructure and 
laboratory facilities are required, which are not common 
to all centers. another limitation is the dilution of the in-
tracellular label as cells divide, which might impair de-
tectability. as no new label can be added to the cells af-
ter transplantation, the imaging window is at maximum 
a few half-lives of the label used, which limits the type 
of questions that can be addressed with direct labeling.
Specific immune cells can also be labeled direct in 
vivo, mostly exploiting the specificity of monoclonal 
antibodies. disadvantages of radiolabeled antibodies in-
clude the non-specific binding by the cells of the reticu-
lo-endothelial system, predominantly in the liver, spleen 
and bone marrow. The slow pharmacokinetic properties, 
e.g. long circulation times and slow tissue penetration, 
of these large proteins often results in an optimal imag-
ing time point a few days after injection, which might 
not cover processes which physiologically occur at more 
dynamic rates, such as receptor expression on cell sur-
faces. The target-to-background ratio is largely depen-
dent on the level of expression, and rate of internaliza-
tion, of the receptor on the target cell population.



































































































































































































































































































































































































































































































































in-ViVo iMaging of TuMor-infilTraTing iMMune cellS Zeelen
Vol. 62 - no. 1 The QuarTerly Journal of nuclear Medicine and Molecular iMaging 59
within 24 hours after the labeling procedure.25 Prince et 
al. reported an efflux of 20% from human dendritic cells 
within the first hour after 64cu-PTSM labeling but did 
not provide efflux rates at later time points. In murine 
Th1 cells labeled with 0.7 MBq of 64cu only a slight 
reduction in viability, IFN-γ secretion, and cell prolif-
eration and an induction of phosphorylated γ-H2AX 
histones was observed. in contrast to adonai et al., who 
proposed the hypothesis that 64cu is mainly retained 
in the cytoplasm, griessinger et al. also found 64cu in 
the cell nucleus.28 The double-strand breaks might be 
caused by the localized radiation within the nucleus be-
cause 64cu decays in 40% by electron capture, emitting 
auger electrons that are radiotoxic to dna.29
Cell labeling with 111In-tropolone.—as an alternative 
to oxine, immune cells have been labeled with 111in-
tropolone for clinical use. More recently, mesenchymal 
stem cells isolated from bone marrow were incubated 
with 111in-tropolone (15-800 Bq/cell).17, 30, 31 The label-
ing efficiency was approximately 25%, yielding 30 Bq/
cell. Within the range 15-260 Bq/cell, doubling time 
was not impaired. however, when using a threefold 
higher dose, the cell proliferation was completely in-
hibited, likely caused by cell death as noted from the 
increased leakage of 111in from the cells. With lower 
doses, the leakage of 111in from the cells was constant 
indicating no induction of cell damage. using 30 Bq/
cell it was possible to label mesenchymal stem cells to 
a level relevant for clinical scintigraphy, without affect-
ing phenotype and differentiation capacity.
Passive incorPoration in the cell membrane
The cell surface membrane is a mosaic of reactive 
groups that allow binding with radiometals and their 
chelator, for example amino-acid residues and thiol 
groups. Such approach to cell labeling, hence not spe-
cific for the cell type, should result in fewer interactions 
with intracellular proteins and processes. recently, sev-
eral approaches have been reported with high clinical 
translational potential.
Cell labeling with 89Zr-DBN.—desferoxamine binds 
stable to free amino-acid residues, also present on the 
outer cell membrane. a novel cell labeling agent, 89Zr-
desferoxamine-ncS (89Zr-dBn), was synthesized. 
time. freshly-prepared 99mTc-hMPao should be used 
for cell labeling (within 20 minutes of preparation) since 
only the lipophilic 99mTc-hMPao complex can freely 
cross the cell membrane and is subsequently trapped in-
side the cell. Two mechanisms have been suggested to 
be responsible for the retention of 99mTc-hMPao inside 
the cell: 1) conversion of the lipophilic 99mTc-hMPao 
complex into a hydrophilic complex by reducing agents 
such as glutathione, and 2) binding of 99mTc-hMPao 
to non-diffusible proteins and cell organelles. Some 
release of 99mTc-hMPao from the labeled cells after 
reinjection into the subject is often observed, resulting 
in undesired accumulation of radioactivity in the gas-
trointestinal and urinary tracts. There is little intestinal 
excretion of 111in-oxine that might have been released 
by the cells; in the clinical setting planar and SPecT 
images obtained with 111in-oxine labeled cells are often 
lower quality than those obtained with 99mTc-labeled 
cells, which requires increased acquisition time. The 
most important disadvantage, however, is the radiation 
exposure of labeled cells, critical organs (spleen) and 
the whole body to 111in-oxine, which is substantially 
higher than that from 99mTc-hMPao. recently, 89Zr-ox-
ine methods have been described in preclinical studies, 
which would increase the sensitivity of detection and 
allow quantification by using PET imaging.
Cell labeling with 64Cu-PTSM.—64cu conjugated to 
PTSM (64cu-PTSM) is an intracellular radiolabel for 
lymphocytes.25 The redox-active carrier molecule 64cu-
PTSM diffuses passively across the cell membrane be-
cause of its lipophilic properties. Within the cytoplasm, 
cu(ii)-PTSM is reduced to the unstable cu(i)-PTSM, 
resulting in the dissociation of cu(i) from PTSM. The 
main step of the cell-labeling process is trapping of the 
released 64cu, which is subsequently bound by intracel-
lular proteins.26 Because the positron-emitting radio-
isotope 64cu has a half-life of 12.7 hours, non-invasive 
cell tracking by PET is feasible for several days. Only 
a few research groups have focused on 64cu-PTSM la-
beling of cells for cell-tracking studies.25, 27, 28 in a de-
tailed characterization of 64cu-PTSM labeled murine 
oVa-Th1 cells in vitro, an efflux of 53% within 5 hours 
and 86% within 24 hours after labeling with 0.7 MBq 
of 64cu-PTSM was observed. in other cell types, ado-
nai et al. performed efflux studies with rat glioma cells 
and detected an efflux of 62% within 5 hours and 78% 
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be exploited by the most widely used tracer in nuclear 
medicine, 2-deoxy-2-fluoro-D-glucose (FDG). After 
entering the cell via the glut-transporter family, phos-
phorylation by hexokinase 6 results in trapping and ac-
cumulation of the tracer in the cell.36 as tumor cells ex-
ploit the same metabolic pathways, ex-vivo labeling is 
unavoidable to discriminate 18f-fdg labeled cells from 
physiologic background glycolysis or uptake by tumor 
cells. however, the short half-life of 18f limits its ap-
plication to image processes that in general span hours 
to days like accumulation of immune cells in inflamma-
tory lesion. Moreover, efflux of 18f-fdg from cells can 
be decreased pharmacologically, for example in neural 
stem cells by using phloretin,37 but leakage of 18f-fdg 
from the cells hampers its use in clinical studies.
active uPtake via endocytic Pathways
Most cells of the myeloid lineage mostly have in-
trinsic capacity to phagocyte nano-sized compounds 
from their environment. This characteristic is exploited 
to label cells with nanoparticles containing an imaging 
contrast agent. nanoparticles are a common denomina-
tor for engineered particles of 10-1000 nm in size, with 
a plethora of different coatings, formulations and con-
tents, both for diagnostic or therapeutic purposes.38-40 
for example, (ultra)small paramagnetic iron oxide (u)
SPio nanoparticles are used for labeling phagocytic 
cells both in vivo for improved lymph node staging 41 
and ex vivo to track therapeutic cells.42 Stannous chlo-
ride colloids have been as carrier for radionuclides to 
more specifically target monocytes, granulocytes or 
stem cells.43
Cell labeling with 99mTc-SnF2.—Phagocytosis of ra-
dioactive colloids has attracted considerable interest as 
a simple method for labeling monocytes and granulo-
cytes with gamma emitting radionuclides for clinical 
studies. Attempts have been made to label leukocytes 
not only with a 99mTc-sulphur colloid.44, 45 Schroth et al. 
first used 99mTc-Snf2 colloids for labeling leukocytes in 
the whole blood.43 Labeling efficiency is significantly 
higher when leukocytes are labeled in vitro with 99mTc-
Snf2 compared with 99mTc-hMPao. This can be ex-
plained by the different uptake mechanisms. 99mTc-Snf2 
is taken up by neutrophils and monocytes by phagocy-
tosis, which might well be less for non-phagocytic cells 
Several cell types, including human immune cells, 
were covalently labeled with 89Zr-dBn via the primary 
amine groups present on cell surface membrane pro-
teins, with a labeling efficiency of 30% to 50% after 30 
min labeling depending on cell type. radioactivity con-
centrations of labeled cells of up to 0.5 MBq/106 cells 
were achieved without a negative effect on cellular vi-
ability. Cell efflux studies showed high stability of the 
radiolabel, with virtual no loss of tracer up to 7 days, 
also the in-vivo stability of the radiolabel on the human 
mesenchymal stem cells was demonstrated.32
Cell labeling with 18F-HFB.—Ma et al. report a 
simple method for cell labeling with 18f, which in-
volves hexadecyl-4-fluorobenzoate (HFB); a lipophilic 
long-chain ester that is absorbed in the cell membrane 
without entering the cytoplasm, in a similar fashion to 
fluorescent dyes used for cell labeling. Cell labeling ef-
ficiency in rat mesenchymal cells was 25% after 30 min; 
but longer incubation times were not investigated. cell 
viability following radiolabeling was found to be >90%, 
with retention >90% over a 4-hour period.33 The in-vivo 
distribution of cells labeled with 18f-hfB was followed 
for 60 min and showed typical distribution pattern to the 
lungs, and no uptake of radioactivity outside the lung 
was observed, supporting efficient retention of the ra-
diolabel in the cells. in contrast, injection of the labeling 
agent itself, 18f-hfB, showed almost complete deposi-
tion of radioactivity in the lower abdomen, likely repre-
senting the organs of metabolism and clearance (liver, 
kidneys).
Cell labeling with 18F-FBEM.—Several cell types ex-
press thiols at their cell surface. Maleimides derivatives 
are well-known thiol scavengers and resulted therefore 
in the generation of 18f-labeled maleimides.34 18f-fBeM 
(18F-4-fluorobenzamido-N-ethylamino-maleimide) re-
acts quickly and efficient with thiols expressed on the 
cell and is highly retained in cells up to ph 9.
active uPtake via endogenous transPorters.
Cell labeling with 18F-FDG.—activated proliferat-
ing lymphocytes rapidly switch to aerobic glycolysis, 
which results in increased glucose uptake. This is fa-
cilitated by the increased localization of the glucose 
transporter (glut1) to the plasma membrane 35 and can 
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diethylenetriaminepentaacetic acid (dTPa), ethylene-
diaminetetraacetic acid (edTa), 1,4,7,10-tetraacetic 
acid (doTa), showed limited stability. dfo has dem-
onstrated to be the most promising with a release of less 
than 0.2% of Zr4+ after 24 hours in serum.51 however, 
in-vivo stability of 89Zr-dfo labeled antibodies remains 
an issue and studies have focused on improving dfo 
linkage to the antibody. An effective approach to con-
jugate DFO to antibodies is modification of DFO by N-
succinimidyl-S-acetylthioacetate (SaTa), which binds 
to antibodies after introduction of maleimide moieties. 
recently, a novel chelator for dfo* was reported that 
shows superior stability and in-vivo performance com-
pared with dfo.52
Indirect radiolabeling strategies
indirect cell labeling strategies are based on the in-
troduction of a gene construct in the host cell that ei-
ther encodes for a specific receptor for uptake of the 
tracer, or for a specific enzyme necessary to entrap the 
tracer intracellular. The indirectly labeled cells should 
exhibit enhanced and specific uptake of the injectable 
tracer once transplanted, which increases detectabil-
ity as compared to the background. Furthermore, as it 
requires intact intracellular machinery, it only images 
viable cells. The transcription can be placed under the 
control of specific promotors, which allow transcription 
under predefined conditions. Also, multiple genes can 
be inserted, only limited by the maximum length of the 
construct, which potentially allow transfecting cells for 
multimodal imaging. lastly, the transfected gene should 
be passed on to daughter cells, thus cell proliferation 
does not result in dilution of the label and longitudinal 
imaging with tracers with short half-life is possible.
disadvantages of indirect cell labeling include the 
need for genetic modification, which require regulatory 
aspects and high level of specific infrastructure, facili-
ties and expertise. Moreover, the level of expression of 
the vector cannot be controlled, both overexpression 
and silencing can occur with unwanted effect on imag-
ing. indirect labeling strategies are currently not being 
used routinely in clinical studies.
The use of imaging modality specific reporter genes to 
visualize cells in vivo is a common strategy in preclini-
cal studies and was summarized in various reviews.53, 54 
Briefly, most studies use the luciferase reporter gene 
types like lymphocytes. The size and nature of radiola-
beled colloids are important parameters to obtain opti-
mal phagocytosis with minimal surface adsorption.46, 47
active uPtake via sPecific recePtors
Cell labeling using chemo- and cytokines.—in gen-
eral, small biological molecules show rapid targeting 
with high affinity and rapid clearance from circulation. 
Moreover, most molecules are internalized by their tar-
get cells, all-contributing to high target-to-background 
ratios. Disadvantages include tracer-specific biodistri-
bution with high uptake in physiological sites, often 
immune-reactive sites. The agent might be biologically 
active, which may lead to side effects in some cases, 
which may limit its application in clinical studies.48
Cell labeling using monoclonal antibodies.—recep-
tor expression on the cell surface is mostly dynamic and 
involves internalization. In-vivo or ex-vivo binding these 
receptors may facilitate the radiolabeling of specific cell 
populations, e.g. 64cu conjugate monoclonal antibodies 
specific for T-cell receptors of CD4+ T-cells,28 or 89Zr 
conjugated diabodies specific for CD8.49 Both radionu-
clides have been studied for tracking human peripheral 
stem cells using anti-cd45 antibodies.50
The main advantage of monoclonal antibodies 
(mAbs) is the high specificity and affinity for their cog-
nate antigen. however, due to their large size, mabs 
have a long circulation time and slowly accumulate in 
the target tissue, imaging should be performed between 
6-24 hours post-injection in mice, and 3-5 days post-
injection in patients to obtain a high target/background 
ratio. disadvantages of radiolabeled mabs include their 
sustained background levels and their nonspecific ac-
cumulation due to the ePr effect. mabs can have a 
mouse origin and can lead to the induction of human 
anti-mouse antibodies (haMa) that affect targeting ef-
ficiency. However, currently used mAbs are humanized 
which circumvents this possible adverse effect.
89Zr-based immune-PeT imaging has demonstrated 
a higher stability in vivo as compared to 124i-labeled 
antibodies and has shown feasibility to monitor cancer 
treatment. 89Zr matches pharmacokinetics of antibodies 
and provides high-resolution imaging. however, an ap-
propriate chelator system is needed to prevent detach-
ment from antibodies. Several used chelators, such as 
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to strict governmental regulations in the use of genetic 
modified organisms in humans. However, advanced vi-
ral vectors for a safe transduction are currently under 
development and will allow a routine use of genetically 
modified cells, e.g. car-T-cells, in patients, and may 
facilitate also the use of reporter genes for imaging.
Imaging tumor-infiltrating lymphocytes
Passive diffusion over the cell membrane
cell labeling with 111in-oxine
The robustness of the 111in-oxinate (half-life 2.8 
days) cell labeling protocols has resulted in routine ap-
plication to migration and homing of 111in-oxine labeled 
T-cells in normal conditions, inflammation and tumor 
environment.48 in a clinical study of 35 patients with 
Hodgkin’s disease, 111in-oxine labeling was exploited 
to investigate the relative cd4+ T-cell lymphocytope-
nia observed in the majority of these patients. Median 
1.0 ×109 (range 0.2 to 2.6 ×109) labeled lymphocytes 
were re-infused with median 6.3 MBq (range 1.9 to 
12.3 MBq) 111in in 17 procedures. 111in-oxine-labeled T-
cells accumulated in 54 of 61 lymphoma localizations 
in enlarged lymph nodes, resulting in increased clear-
ance from the blood pool in patients with active dis-
ease as compared to patients in remission,57 supporting 
the concept of specific sequestration of CD4+ T-cells in 
lymphoma lesions.
The preferential accumulation of ex-vivo expanded 
tumor-infiltrating lymphocytes (TIL) was studied in 6 
melanoma patients with adoptively transferred 111in-
oxine labeled Til. after cyclophosphamide pre-treat-
ment, 4.4 to 13 ×109 radiolabeled cells were re-infused 
with 8.6 to 14.8 MBq 111in. Serial scintigraphy imaging 
showed progressive accumulation of 111in-oxine labeled 
Til from 24 hours to 115 hours post-injection in most 
lesions, varying from 3 to 40 times background level.58 
The same group studied in 18 melanoma patients treated 
with cyclophosphamide preconditioning and il-2 injec-
tions after adoptively transferred TILs, the tumor-infil-
trating capacities of Tils as compared to unselected pe-
ripheral blood lymphocytes (PBl).59 a wide range of 4.4 
to 14 ×109 cells were re-infused with 55 to 255 kBq/108 
cells 111In, and the authors noted a remarkable difference 
in tumor-infiltration as TILs accumulated in melanoma 
lesions on 13/18 scans and PBls only in 1/4 scans.
and fluorescence proteins (green or red fluorescence 
protein) for bioluminescence or fluorescence optical 
imaging. The ferritin receptor and the transferrin recep-
tor represent reporter genes, which can be applied to 
visualize cells by Mri.55
cell imaging using hsv1-tk rePorter genes
Besides, several reporter gene strategies are available 
for SPecT and PeT, which mainly comprises enzymes 
(herpes-simplex virus thymidine kinase 1; HSV1-tk), 
receptors (dopamine d2 receptor, somatostatin recep-
tor) or transporters (sodium-iodine symporter, niS). 
The application of the hSV1-TK in combination with 
specific substrates 9-[4-18f-3-(hydroxymethyl)butyl]
guanine (18f-fhBg), 2-deoxy-2-18f-5-ethyl-1-d-ara-
binofuranosyluracil (18f-feau) or 2-deoxy-2-18f-5-io-
do-1-d-arabino-furanosyluracil (18f-fiau) is the most 
commonly used reporter gene system to visualize cells 
by PET. The HSV1-tk represents also a suicide gene to 
target transfected cells with the virostatic agent ganci-
clovir, because the enzyme is naturally not expressed in 
eukaryotic cells. This represents also one drawback, as 
the hSV1-TK will be recognized as foreign antigen by 
the human immune system, which will result in an elim-
ination of the therapeutic transferred cells by the host 
immune system. The substrates for the hSV1-TK are 
most likely taken up by nucleoside transporters, which 
may influence the cellular uptake due to the number of 
expressed transporters on the cell membranes. once, the 
substrate has entered the cell, it will be phosphorylated 
by the hSV1-TK and thus is trapped within cells.56
cell imaging using nis rePorter genes
another common example for a PeT/SPecT reporter 
gene is niS, which is originally expressed in a few hu-
man tissues (e.g. thyroid). By the application of 124i for 
PeT, 125i for SPecT or other tracers (e.g. 99mTc-pertech-
netate) the cells can be visualized due to the active up-
take of the radioactive iodine. However, the stability of 
the tracer within the cells is not very high because no 
active trapping occurs in the cells. furthermore, due to 
its natural occurrence in human tissue, the niS will be 
not immunogenic.
a general clinical application of genetically modi-
fied cells is currently limited to specialized clinics, due 
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tumors of a mouse melanoma model, for up to 4.6% of 
the total injected activity, which significantly resulted in 
tumor regression at day 7 after injection.63 following a 
different radiochemical approach, 89Zr-oxinate was also 
used to label other immune cell populations, like human 
leucocytes.62
cell labeling with 64cu-Ptsm
64cu-PTSM has been used for extended cell tracking 
in lymphocytes, which were observed to accumulate 
in spleen, liver, bone marrow and the tumor site in a 
mouse glioma model.25 64cu-PTSM labeling of mouse 
Th1 cells showed to be a highly sensitive method for 
in-vivo monitoring of T-cell homing for up to 48 hours, 
without affecting critical cell functions. highest cell vi-
ability and labeling efficiency was achieved by labeling 
oVa-Th1 cells for 3 hours with 0.7 MBq per 1 ×106 
cells. intraperitoneal injected oVa-Th1 cells distribut-
ed to the perithymic lymph nodes, whereas intravenous 
injection of 64cu-oVa-Th1 cells resulted in homing in 
the lungs and spleen.28 The accumulation of 64cu-oVa-
Th1 cells in the pulmonary lns 24 hours after injection 
was highest in the oVa-immunized and -challenged 
airway hyperreactivity-diseased mice after intraperi-
toneal administration. Moreover, 64cu-oVa-Th1 cells 
also accumulated significantly in the pulmonary LNs of 
non-immunized oVa-challenged mice as compared to 
control mice.
in order to maximize the retention of the 64cu la-
bel, T-cells have been electroporated with 64cu2+ gold 
nanoparticles and imaging in in-vivo models demon-
strated high potential in evaluating immunotherapy.64 
This method could circumvent the extended time re-
quired for internalization of nanoparticles by endocyto-
sis, which is a practical limitation for radionuclides with 
short half-life.
in general, these mentioned labeling approaches suf-
fer from a low stability in vivo, which limits their ap-
plicability for imaging scarce cell populations over pro-
longed periods of time.
Passive incorporation in the cell membrane
cell labeling with 18f-fbem
covalent binding of functional groups on the cell 
membrane has the advantage of stable labeling of cells 
Pittet et al. showed that 111ln-oxine labeled cytotoxic 
T-cells (cTl), allows semi-quantitative assessment and 
localization of cTl in a mouse model, bearing both 
hemagglutinin (ha)-negative and ha-expressing tu-
mors. 111In-oxine labeled CTLs specific for HA redis-
tributed to ha-expressing tumors after 2 hours with 
continuous increase for up to 120 hours post-injection. 
Moreover, HA-specific CTL localized centrally in HA-
positive tumors, as opposed to cTl in ha-negative 
tumors, which remained at the periphery of the tumor. 
These findings are consistent with earlier observations 
by intravital microscopy which showed the requirement 
of tumor specific antigen expression for deep infiltra-
tion of cTl.60
cell labeling with 99mtc-hmPao
99mTc-hMPao labeling has not been employed for 
the study of tumor-infiltrating lymphocytes, likely be-
cause the shorter half-life of 99mTc (6 hours) as com-
pared to 111in (2.8 days). however, in a preclinical 
model of subcutaneous injections of oVa-pulsed or 
non-pulsed dendritic cells that migrate to the inguinal 
lymph nodes, it was noted that 99mTc-hMPao labeled 
OVA-specific CD4+ T-cells migrate specifically to the 
lymph nodes that contain oVa-pulsed dendritic cells 
within 3 hours.61
cell labeling with 89Zr-oxine
although the relatively long half-life of 111in allows 
longitudinal tracking of labeled cells in processes that 
typically require multiple days, the low sensitivity and 
poor spatial resolution of the gamma camera imaging/
SPECT is insufficient for more advanced applications 
and imaging of scarce cell populations. recently, sev-
eral procedures to label cells with 89Zr have been de-
scribed.32, 62, 63 These methods offer a potential solution 
to the emerging need for a long half-life PeT tracer for 
quantitative imaging of immune cells exploiting the im-
proved sensitivity of PeT scanners.
89Zr-oxine labeling was demonstrated to not affect 
cTl survival, proliferation and function. in preclini-
cal models, 89Zr-oxine labeled T-cells (185 kBq/5 ×106 
cells) first were trapped in the lungs, but subsequently 
redistributed to spleen, lymph nodes and liver. after 6 
hours, 89Zr-oxine labeled cTls started to accumulate in 
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(18f-fac). direct in-vivo labeling showed enhanced 
uptake by lymphoid organs and rapidly proliferating 
tissues in which the salvage pathway is predominant 
for dna synthesis. as most other tissues rely on the 
de novo pathway for dna synthesis, 18f-fac showed 
a more selective uptake in lymphoid organs than other 
nucleoside metabolism tracers such as 18f-flT and 18f-
fMau.69, 70 Proliferating T-cells utilize 10-fold more 
glutamine than any other amino-acid to regenerate 
oxaloacetic acid which is consumed by biosynthesis.35 
Magnetic resonance spectroscopy (MrS) and serum 
analysis of 1h-nMr and 19f-nMr have been used for 
imaging the bio distribution of T-cells by detecting the 
metabolites associated with increased glycolysis in in-
flammation.71, 72
Active uptake via endocytic pathways
Because of the low phagocytic activity of T-cells, 
cationic transfection agents like poly-L-lysine or cell 
penetrating peptides that enhance endocytosis, like Tat 
peptides or protamine, are required for sufficient intra-
cellular labeling of imaging tracers. Most studies that 
exploit endocytosis for cell labeling include single or 
multimodal imaging tracers which are formulated in 
(nano)particles.
cell labeling with 89Zr-chitosan nanoParticles
Chitosan nanoparticles are taken up by cells via 
various endocytic pathways.73 exploiting these mech-
anisms, chitosan-nanoparticle constructs have been 
shown to bind 89Zr and thereby deliver 89Zr into hu-
man leucocyte populations with labeling efficiencies of 
65.5%, for nanoparticles of different molecular weights.
cell labeling with (ultra) small iron oxide Par-
ticles
T-cells labeled with small iron oxide particles (SPio) 
demonstrated high sensitivity as even single cells could 
be detected at 9.4T in confined localizations in the sub-
ject.74, 75 in a preclinical study, ovalbumin (oVa) spe-
cific lymphocytes labeled with SPIO particles were 
adoptively transferred into mice with oVa-expressing 
tumors. More than 95% of cells remained viable after 
the labeling procedure and did not affecT-cell prolifera-
as long as they are intact, and without perturbing in-
tracellular processes. Ex-vivo 18f-fBeM labeling of T-
cells has been described with no effect on viability and 
physiological biodistribution mainly to the spleen, after 
intravenous injection in a mouse model.34 in a follow-
up study by the same group, in a mouse model for id-
iopathic pulmonary fibrosis, they demonstrate recruit-
ment of 18f-fBeM labeled leucocytes, predominantly 
lymphocytes, to the inflamed lung.65
Active uptake via endogenous transporters.
cell labeling using 18f-fdg
early studies demonstrated a reasonable labeling ef-
ficiency of 18f-fdg of approximately 55-70% in lym-
phocytes (with 30-40 MBq per 2.5 ×108 cells). This 
would allow tracking of the cells for 24-36 hours. How-
ever, this strategy precludes long term imaging due to 
its short half-life of 18f, probe dilution by proliferation 
and release from the cell by phosphatase activity.66
cell labeling targeting other metabolic Pathways
exploiting metabolic pathways is intrinsically an in-
teresting approach for cell labeling as these processes 
are in general very efficient, and occurs only in living 
cells. Furthermore, metabolic profiles reveal the func-
tional orientation of cells, which may provide additional 
information. Several tracers, with specificity for lym-
phocyte metabolism, are being developed for in-vivo 
imaging, but have so far not been tested for evaluation 
of tumor-infiltration. 18f-flT is a thymidine analogue 
that correlates with DNA synthesis as it is taken up in 
the cell where it is phosphorylated by thymidine ki-
nase.67 in melanoma patients who underwent dendrit-
ic cell-based vaccinations, signal intensity of 18f-flT 
PeT/cT correlated with the lymphocyte response as 
measured by immune assays in peripheral blood.68
another PeT tracer that is selectively incorporated 
in dna during synthesis is 18F-1-(2-deoxy- 2-fluoro-
d-arabinofuranosyl)thymine (18f-fMau). increased 
radioactivity was detected in fast proliferating tissues, 
lymph nodes and the bone marrow where it is highly 
resistant against degradation, indicating its potential 
to visualize T-cells.69 A novel probe that specifically 
targets activated T-cells is the nucleoside analogue 
1-(2’-deoxy-2’-18f-fluoroarabinofuranosyl)-cytosine 
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with a prolonged intracellular retention was achieved 
while low toxicity was reported.80
Genetically modified T-cells expressing chimeric 
antigen receptors (car) exert anti-tumor effect by 
identifying tumor-associated antigens. for maximal ef-
ficacy and safety of adoptively transferred cells, in-vivo 
assessment of their biodistribution is critical. This will 
determine if cells home to the tumor and assist in opti-
mizing cell dosing. a method is developed for loading 
high cell number with multi-modal (PeT-Mri) contrast 
agents (e.g. SPion-64cu), which could potentially be 
used for 64cu-based whole-body PeT to detect T-cell 
accumulation region with high-sensitivity, followed by 
SPion-based Mri of these regions for high-resolution 
anatomically correlated images of T-cells. cd19-specif-
ic car-T-cells labeled with SPion effectively target 
in-vitro cd19+ lymphoma.81
Active uptake via specific receptors
receptor expression on the cell surface is mostly dy-
namic and involves internalization and/or activation of 
the downstream signaling pathways. In-vivo or ex-vivo 
binding these receptors may facilitate the radiolabeling 
of specific cell populations
cell labeling using radiolabeled cytokines and 
chemokines
once activated and regulatory T-cells express in-
creased numbers of receptors involved in activation 
signaling and chemotaxis. following their physiologi-
cal role, these mediators often have high affinity for 
their cognate receptors expressed on inflammatory 
cells, which renders them interesting candidates for 
in-vivo imaging. The most investigated receptor is the 
interleukin (IL)-2 receptor, named CD25, highly ex-
pressed on activated T-lymphocytes. as early as the 
1980’s, il-2 has been labeled with various isotopes, 
(i.e. 123i, 125i, 99mTc, and 18f) and tested in animal mod-
els. clinical studies using radiolabeled il-2 involve pa-
tients with a wide variety of inflammatory conditions 
like inflammatory bowel disease, diabetes, atheroscle-
rotic plaques and melanoma patients. radiolabeled il-2 
is the only cytokine that has been investigated in human 
cancer. activated T-lymphocytes show an increased 
expression of the il-2 receptor and il-2 labeling can 
tion. Twenty-four hours after injection, the signal was 
increased in the spleen and a significant increased signal 
was seen in the tumor after 24 hours until 72 hours after 
injection. The OVA specific T-cells induced regression 
of oVa-positive tumors compared to oVa-negative tu-
mors.75 a similar study was done with highly deriva-
tized cross-linked iron oxide nanoparticles (CLIO-HD) 
that were used to label adoptively transferred T-cells in 
a melanoma mouse model. High labeling efficiency was 
achieved without affecting the function of T-cells. 3d 
Mri showed recruitment of T-cells in the tumor with 
high resolution.53, 76, 77
cell labeling with 19f-based agents
19F-containing perfluorocarbon (PFC)-based label-
ing approaches are analogous to those used for SPio 
and allow imaging with 19F MR. PFC-based cell track-
ing enables cell detection with high specificity and al-
lows quantification due to the absence of background 
signal because of the low concentration of naturally oc-
curring 19f in the body.74, 78 cell detection sensitivity is 
estimated to be in the order of 104 to 105 cells per voxel 
in clinical setting.78
cell labeling using multimodal nanoParticles
Dual mode fluorescently labeled PFC allows visu-
alization of the fate and phenotype of the label with 
fluorescence imaging in addition to MRI. A study that 
showed that this approach is effective in labeling and 
subsequent imaging of T-cells used BodiPy-Tr PfPe 
nano-emulsions as dual mode tracer.79 confocal micros-
copy confirmed presence of the nano-emulsion within 
T-cells. fluorescence intensity showed a linear correla-
tion with the 19f nMr signal, which demonstrates the 
potential for using fluorescence imaging for quantifica-
tion purposes. injection of labeled cd4+ T-cells showed 
accumulation to lymph nodes in mice, which was con-
firmed by isolation of lymph nodes and microscopic 
analysis of cells.79
another dual mode imaging approach that is prom-
ising for in-vivo tracking of T-cells in high-resolution 
MRI makes use of cross-linked iron oxide nanoparticles 
(clio). Tat peptides which are internalized in cells by 
adsorptive endocytosis, were coupled to clio particles 
that carried a fluorochrome. High labeling efficiency 
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pared to both the untreated mice and the mice injected 
with an isotype-matched control antibody. furthermore, 
total remission occurred in 30% of mice receiving a low 
dose (2.8 MBq of 90y labeled 7g7/B6) and 75% in the 
high-dose group (5.6 MBq), whereas all mice in the 
control group died.84
cell labeling using antibody fragments
antibody fragments, such as the diabodies (db) and 
minibodies (Mb), typically have half-lives that range 
from 2 to 5 hours and from 5 to 12 hours, respectively. 
This is an advantage over intact antibodies with half-
lives of up to 3 weeks. Although the total uptake in tu-
mors is decreased with antibody fragments, the rapid 
clearance of engineered antibody fragments still results 
in higher tumor-to-background ratios at earlier time 
points. Moreover, antibody fragments lack Fc-effector 
functions and thus are biologically inert.
64Cu-conjugated minibodies specific for CD8 have 
been constructed from the variable regions of two an-
ti-murine cd8-depleting antibodies. The minibodies 
(Mbs) bound to primary cd8+ T-cells from the thymus, 
spleen, lymph nodes, and peripheral blood. importantly, 
this approach did not result in depletion of cd8+ T-cells 
in vivo. in a series of experiments, these 64cu-radiola-
beled Mbs produced high-contrast immuno-PeT images 
4 hours post-injection and showed specific uptake in the 
spleen and lymph nodes of antigen-positive mice.85 By 
the same group, 89Zr-desferoxamine–labeled anti-cd8 
cys-diabodies (89Zr-maldfo-169 cdb) were generated 
for PET imaging of tumor-infiltrating CD8+ T-cells. us-
ing this tool changes in systemic and tumor-infiltrating 
cd8 expression were detected in different preclinical 
syngeneic tumor immunotherapy models, including 
antigen-specific adoptive T-cell transfer and checkpoint 
blockade antibody therapy targeting PD-L1.49
in another example, human Tcr-transgenic T-cells 
were tracked in vivo by directly targeting the murinized 
constant Tcr beta domain (Tcrmu) with a 89Zr-labeled 
anti–Tcrmu-f(ab’)2 fragment. using a murine xeno-
graft model of human myeloid sarcoma, the authors 
monitored the presence of human central memory T-
cells, which were transgenic for a myeloid peroxidase-
specific TCR. Diverse T-cell distribution patterns were 
detected by PeT/cT imaging, depending on the tumor 
size and rejection phase. Results were confirmed by im-
therefore be used for T-cell tracking. 123i- and 99mTc-
labeled il-2 have demonstrated to image lymphocytic 
infiltration in several inflammatory diseases as well as 
in melanoma.82, 83
cell labeling using monoclonal antibodies
Several monoclonal antibodies (mAbs) for specific 
cell types have been used, targeting e.g. cd45, cd3, 
cd4 and cd8.48 Both PeT and SPecT imaging dem-
onstrated to successfully detect T-cell infiltration in a 
variety of diseases, including infiltration in cancer le-
sions. Making ultimate use of the specificity of mAbs, 
this strategy has also been investigated to label T-cell 
populations expressing a specific T-cell receptor in 
a preclinical mouse model.28 using a T-cell receptor 
(TCR)-specific labeling approach, Griessinger et al. 
showed that continuous Tcr plasma membrane turn-
over and the endocytosis of the specific 64cu-mab-Tcr 
complex enables a stable labeling of T-cells. The Tcr-
mab complex was internalized within 24 hours, and 
no detrimental effects on antigen recognition, viability, 
dna-damage and apoptosis or effector function were 
noted. This approach enabled to follow and quantify the 
specific homing of systemically applied 64cu-labeled 
chicken ovalbumin (cOVA)-TCR transgenic T-cells into 
the pulmonary and perithymic lymph nodes (lns) of 
mice with coVa-induced airway hyper-reactivity, but 
in a reduced amount into pulmonary and perithymic 
LNs of naïve control mice or mice diseased from turkey 
or pheasant oVa-induced airway hyper-reactivity. This 
labeling approach is theoretically applicable to other 
cells with constant membrane receptor turnover and 
highly interesting for the detection of small numbers of 
immune cells with preferential homing to specific local-
izations like lymph nodes and tumor lesions.
The specific targeting of CD25, expressed on acti-
vated lymphocytes in leukemia patients is especially 
interesting as anti-cd25 mabs have been labeled for 
diagnostic and therapeutic purposes. Zhang et al. dem-
onstrated the potential clinical relevance of the anti-
cd25 monoclonal antibody 90y-labeled 7g7/B6 as a 
radio-immunotherapy for cd25-expressing lympho-
mas. 111In-labeled 7G7/B6 significantly accumulated in 
the tumor of a mouse lymphoma model, with the high-
est concentration at 48 hours. Mice injected with 90y-
labeled 7g7/B6 showed a prolonged survival as com-
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to radioactivity did not affect cell viability, pheno-
type or function. next, adoptively transferred Treg-niS 
in c57Bl/6 mice were imaged in the spleen after 24 
hours.61
Moroz et al. compare in a recent study the labeling 
of T-cells by comparing the efficiency of the reporter 
genes norepinephrine transporter (hneT), human niS, 
a human deoxycytidine kinase double mutant (hdCK-
DM), and the HSV1-tk. After injection the combination 
of the hNET and its specific tracer 18f showed the high-
est sensitivity, detecting 35-40 ×103 T-cells in vivo.15
Imaging tumor-infiltrating NK cells
Passive diffusion over the cell membrane
direct nK cell labeling can be achieved by using 
either 111in-oxine or 99mTc-hMPao. first studies from 
Meller et al. were performed in patients with renal cell 
carcinoma. They received 3 to 7 ×107 nK cells labeled 
with 111in-oxine together with a 10-fold excess of unla-
beled nK cells obtained from allogeneic donors. Whole 
body images were obtained 0.5-144 hours post-injection 
and detected labeled nK cells in two of four large me-
tastases. nK cells were still detected in the blood up to 3 
days after injection, as confirmed by PCR, but always in 
low numbers.91 Brand et al. performed 111in-oxine nK 
cell scintigraphy in patients with renal cell carcinoma 
showing their accumulation in 2 out of 4 cancer lesions. 
Since signal half-life remained almost constant over the 
6 days they hypothesized an extended survival of the 
transfused cells.92
imaging of nK cells generated from umbilical cord 
blood (ucB) cd34+ hematopoietic progenitor cells 
for anti-leukemia immunotherapy, has been performed 
following adoptive transfer in immunodeficient NOD/
Scid/il2rg(null) mice. a somewhat higher dose of 
0.4 MBq of 111in-oxinate was added to 106 cells, with 
labeling efficiency exceeding 80%, cell viability >90% 
and cell recovery >95%. in addition, this procedure 
did not affect the migration capacity of ucB-nK cells 
towards the prototypic BM-chemokine CXCL12 in vi-
tro.93
Melder et al. labeled nK cells with 11c-methyl-iodide 
to track activated NK cells in a mouse fibrosarcoma 
model and compare their biodistribution to non-activat-
ed splenic lymphocytes. after 30-60 minutes, 4-30% 
of the injected dose was present in the tumor. although 
munohistochemistry and semi quantitative evaluation 
of T-cell infiltration within the tumor corresponding to 
the PeT/cT images.86
IndirecT-cell labeling approaches for lymphocytes
a PeT reporter gene encodes a protein that medi-
ates the specific accumulation of a PET reporter probe 
(PrP) labeled with a positron-emitting radionuclide. 
Prgs developed to date encode proteins with various 
activities, including enzymes, transporters, and recep-
tors.87 The most commonly used Prgs are based on 
herpes simplex virus type 1 thymidine kinase (HSV1-
tk). Several PRPs can be used to image cells engineered 
to express HSV1-tk-based PRGs: 18ffhBg, 18f-feau 
and 18F-FIAU. To date, HSV1-tk is the only PRG that 
has been used to visualize intracerebral injected hSV-
TK1 expressing cd8+ T-cells in a patient with glioblas-
toma by using the substrate 18f-fhBg.88 The main con-
cern of HSV1-tk as a PRG is its immunogenicity, which 
can lead to immune-mediated elimination of transfected 
immune cells. Replacing the viral kinase with a human 
orthologue might solve this, although such approach in-
troduces other issues concerning the level of expression 
as compared to normal tissue and possible switch of en-
gineered cells to “suicide mode.” campbell et al. devel-
oped a mutant Prg enzyme, using structure guided en-
zyme engineering, which is orthogonal to the wild type 
enzyme regarding its ability to phosphorylate endoge-
nous nucleosides.89 This TK2 double mutant efficiently 
phosphorylates l-18f-fMau and has lower activity 
for the endogenous nucleosides thymidine and deoxy-
cytidine than wild type TK2. imaging studies in mice 
indicate that the sensitivity of this new human Prg is 
comparable with that of a widely used Prg based on 
HSV1-tk. The first clinical studies are awaited.
Human deoxycytidine kinase triple mutant (hdCK-
3mut) has been used as a PeT reporter by co-expression 
with the anti-melanoma T-cell receptor f5. In-vivo PeT 
imaging enabled monitoring of tumor infiltration with-
out affecting the T-cell function.90
regulatory T-cells (Tregs) lines derived from 
cd4+cd25+foxP3+ cells have been retrovirally trans-
duced with a construct encoding for the human niS 
and the fluorescent protein mCherry. NIS expressing 
self-specific Tregs were radiolabeled in vitro with 99mTc-
pertechnetate (99mTc-o4-) and exposure of these cells 
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cells into tumor-bearing mice, digital autoradiography 
showed an increased uptake of radioactivity in HER2/
neu-positive tumors. conversely, the parental nK-92 
cells did not accumulate in tumor tissue.96
Active uptake via endocytic pathways
Daldrup-Linket al. et al. optimized labeling of hu-
man nK-92 cells directed against her2/neu receptors 
with SPios ferumoxide and ferucarbotran in mice with 
her2/neu positive mammary tumors imaged with Mr.96 
labeling with both ferumoxide and ferucarbotran (1 
×106 cells at a dose of 100-300 μg Fe) was effective us-
ing lipofection and electroporation techniques but not in 
simple incubation. Intracellular cytoplasmic uptake was 
significantly higher using ferucarbotran. They showed a 
progressive signal decline in the tumors after injection 
with these nK cells that were directed against the re-
ceptors but not after injection with control nK-92 cells, 
confirmed by histopathology.
The intra-arterial delivery of SPio-labeled nK cells 
(100 pg iron/cell suspensions of feo label-Texas red 
with 4.5 μg/mL protamine sulfate) in hepatocellular 
carcinoma in rats, was tested by Sheu et al. labeling 
efficiency was 88±3.1% with a decreased cell viabil-
ity when using higher SPio incubation concentrations. 
This study showed that intra-arterial injection of nK 
cells permits selective delivery with a significantly in-
creased nK cell dose delivered to the tumor, which can 
be visualized as T2* measurement reduction using Mri 
supported by histology.96
Meier et al. used a similar approach as Tavri et al. 
against epithelial cells in rat xenografts, but used SPio 
ferumoxides as labeling technique. in their study 1.5 
×107 nK cells were injected intravenously with a sig-
nificant decline of tumor cells within 24 hour measured 
using contrast to noise ratio as confirmed by histopa-
thology.96
Jang et al. demonstrated the use of an external mag-
netic field using a neodymium magnet to perform near 
infrared fluorescent imaging of Cy5.5-conjugated 
fe3o4/Sio2 nanoparticle-labeled nK cells in mice bear-
ing a human tumor xenograft. This method of applying 
a magnet on the outside of the tumor increased the in-
filtration of magnetic NK cells from 2% to 34% within 
10 minutes.104 When the magnet was removed, the cells 
migrated away from the tumor within minutes caused 
variable, this is higher than 3-4% of the non-activated 
splenic lymphocytes.97
a new pre-clinical approach has been applied by 
Malviya et al., who expanded in-vitro murine nK cells 
and radiolabeled them with 111in-oxine. They showed 
that labeling with 0.011 MBq of 111in-oxine per 106 
murine NK cells provided optimal labeling efficiency 
without affecting cell viability or functionality.94 a total 
of 1 ×106 freshly isolated and labeled cells were then 
re-infused in a human lung cancer mouse model. Mice 
with lung cancer showed higher tumor uptake of labeled 
nK cells than control mice. Mice that were irradiated 
showed a decrease of labeled cells in the tumors be-
tween 24 hours and 72 hours post-injection, which was 
accompanied by tumor regression. non-irradiated mice 
showed no decrease in labeled cells but also no tumor 
regression up to 72 hours after injection. as a control, 
mice that received no nK cells were irradiated and 
showed a high tumor burden 72 hours after injection, 
suggesting that the combination of both radiation and 
nK cell injection has the best antitumor effect in this 
mouse model.94
Passive incorporation in the cell membrane
despite the lower translational potential in humans, 
optical imaging can be performed in pre-clinical mod-
els to evaluate NK cell trafficking with no radiation 
exposure to operator. To this purpose, Tavri et al. used 
near-infrared dye did (1,19-dioctadecyl-3,3,39,39-
tetramethyl-indodicarbocyanine) to label nK cells tar-
geting epithelial cell adhesion molecule antigen in hu-
man prostate cancer xenografts in rats.95 In-vitro studies 
showed a persistence of fluorescent labels over a period 
of 24 hours without significant change in cell viability. 
In-vivo studies showed a significant increase of fluores-
cent signal in the xenograft tumors 24 hours after fluo-
rescent NK cell injection as also confirmed by fluores-
cence microscopy.
Active uptake via endogenous transporters
18f-fdg labeling was also attempted to study the 
biodistribution of nK-92 cells and nK-92 cells geneti-
cally modified to express a chimeric antigen receptor 
that is specific to the tumor-associated ErbB2 (HER2/
neu) antigen. after injection of 5 ×106 ErbB2-specific 
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genes have also been used to label effector nK cells and 
monitor their homing to tumor sites.100
Imaging tumor-associated macrophages
Tumor-associated macrophages (TaMs) are a major 
cell population within the tumor microenvironment, 
which play a multifaceted role in various stages of tu-
mor progression. Macrophages are functionally plastic 
and can alter their polarization state to accommodate 
different physiological conditions. TaMs may originate 
from tissue-specific mononuclear phagocytic cells, e.g. 
alveolar macrophages, Kupffer cells that reside in the 
tissue at pre-cancerous stages. however, the majority 
of TaMs at clinical overt stages of disease originate 
from recruited circulating monocytes with inflamma-
tory phenotypes 101, 102 and acquire their functional phe-
notypes by interacting with the tumor microenviron-
ment.111 at the extremes of their phenotypic continuum, 
macrophages range from M1 to M2 polarization states: 
classically activated M1 macrophages produce type i 
pro-inflammatory cytokines, participate in antigen pre-
sentation and have an anti-tumorigenic role. converse-
ly, “alternatively-activated” M2 macrophages produce 
type II cytokines, promote anti-inflammatory responses 
and have pro-tumorigenic functions.
for example, at the leading edge of tumors, TaMs 
facilitate tumor cell invasion through a paracrine sig-
naling loop that involves tumor-derived colony stimu-
lating factor 1 (cSf-1) and macrophage derived epi-
dermal growth factor (egf). Beyond the leading edge, 
TaMs are the major source of proteases; further sup-
porting tumor progression and tumor motility. further-
more, tumor vascularization requires the co-operation 
of multiple TMe cell types, including TaMs, releas-
ing pro-angiogenic signals into the TMe. Similarly, in 
lymphangiogenesis, another mode of vascularization in 
tumors and an alternative route for cancer cell dissemi-
nation, activated macrophages produce Vegf Beyond 
the initial acquisition of invasiveness in primary tumors 
and the contribution to infrastructural vascularization, 
the next major step in the metastatic cascade is intrava-
sation into circulation. in the tumor core, macrophages 
localize to blood vessels, where they help tumor cells 
intravasate into the circulation. Moreover, the density 
of clusters of TaMs, endothelium and tumor cells cor-
relates with distant metastasis.103, 104
by blood flow. Unfortunately, this approach cannot be 
applied to in deep tumor lesions.
Mallett et al. used MRI to track subcutaneously in-
jected nK cells labeled with Moldayion rhodamineB 
in nude mice with humane prostate cancer. loss of sig-
nal was observed in tumor areas after 24 hours up to 4 
days after injection. histology showed more nK cells in 
the center of the tumor but this could not be seen in the 
Mri images.97
The use of 19f-Pfc has also been explored to la-
bel and track NK cells in preclinical models. Human 
NK cells were expanded with interleukin-2 (IL-2) 
and labeled in vitro with increasing concentrations 
of 19f-Pfc and doses as low as 2 mg/ml 19f were de-
tected. higher doses of 19f up to 8 mg/ml, led to an 
improved 19f signal by Mri with 3 ×1011 19f atoms 
per nK cell, without affecting cell function. 19f-la-
beled nK cells were detectable immediately by Mri 
after intratumoral injection in nSg mice up to 8 days. 
When 19f-labeled nK cells were injected subcutane-
ously, a gradual loss of signal at the site of injection 
suggested their migration to distant organs.98
Active uptake via specific receptors
monoclonal antibodies
a 99mTc-anti-cd56 mab has been used to target and 
follow the trafficking of human NK cells inoculated in 
Scid mice bearing human cancer. nK cells accumulat-
ed in the tumor within 24 hours and were imaged as early 
as 3 hours after intravenous administration of 99mTc-an-
ti-cd56. a positive correlation was observed between 
T/B ratio calculated on tumor lesions and TINKs infil-
tration. however, no correlation was found between the 
number of injected nK cells and their number in the tu-
mor. However, larger tumors were more infiltrated and 
showed more nK cell induced necrosis.99
anti-cd56 antibodies were also used to coat quan-
tum dots for fluorescent imaging of human NK cells.
Indirect labeling of NK cells
In-vivo bioluminescence imaging (Bli) can detect 
small numbers of cells noninvasively and enables the 
quantification of tumor growth within internal organs 
with fusion genes that encode bioluminescent and fluo-
rescent reporter proteins. Such dual function reporter 
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cell labeling using 99mtc-hmPao
Similar to leukocyte labeling, monocytes have been 
labeled with 99mTc-hMPao for the purpose of infection 
and inflammation imaging.109 To our knowledge, no ap-
plication of 99mTc-hMPao in cancer imaging has been 
reported.
Passive incorporation of the cell membrane
The lipophilic tracer 1,1-dioctadecyl-3,3,3,3-tetra-
methylindotricarbocyanine iodide (dir), used in near 
infrared (nir) imaging is passively incorporated in the 
lipid bilayer of the cell membrane. one advantage of the 
use of near infrared imaging is that it has relatively low 
noise. eisenblätter et al. used prelabeled macrophages 
with DiR to localize inflammation in a mouse model 
with cutaneous granuloma and measured the signal with 
two NIR imaging techniques; fluorescence reflectance 
imaging and fluorescence-mediated tomography. In this 
study they found a linear correlation between the num-
ber of cells injected intravenously and the signal ob-
tained with nir imaging.110 The lack of ionizing radia-
tion and signal decay offers potential of such approach 
for cancer research.
Active uptake via endogenous transporters
cell labeling using glut1
The highly plastic nature of macrophages results in 
a plethora of phenotypes, with bioenergetic profiles ac-
cording to the specific environmental stimuli.111 Pro-
inflammatory macrophages are heavily dependent on 
aerobic glycolysis, whereas macrophages with a tissue-
repair phenotype rely on oxidative phosphorylation. as 
such, TAMs might contribute significantly to the total 
tumor glycolysis.112-114 however, to accurately attri-
bute 18F-FDG uptake in the tumor microenvironment to 
either tumor cells or TaMs remains challenging. in a 
clinical trial preoperative 18f-fdg PeT imaging in 55 
breast cancer patients was compared to histochemical 
staining for macrophage markers on tumor sections.115 
no correlation between 18F-FDG-uptake and presence 
of macrophages was noted. TaMs have high prognostic 
impact in classical Hodgkin lymphoma,116 but studies 
that correlate early response to treatment as measured 
by 18f-fdg PeT with the presence of cd68+ TaM 
from an imaging perspective, the high phagocytic and 
storage capacity of TaMs allows loading with imaging 
contrast containing nanoparticles to reach high intracel-
lular concentrations for optimal signal-to-background 
ratios. Moreover, as these cells hardly proliferate in the 
tumor microenvironment, label dilution and subsequent 
loss of signal is less of a problem. challenging however 
is to pinpoint specific functional phenotypes that can be 
present in the tumor-environment simultaneously.
Passive diffusion over the cell membrane
cell labeling using 111in-oxine
The high abundance of tumor-associated macrophages 
in renal cell carcinoma prompted studies with therapeu-
tic infusion with monocyte-derived macrophages in renal 
cell carcinoma patients. Monocytes were differentiated 
ex vivo with granulocyte-macrophage colony-stimulating 
factor (GM-CSF) and short pulse of IFN-γ for a total of 
7 days before re-infusion. To study their tumor homing 
capacity, Quillien et al. labeled these cells applying 15 
MBq 111in-oxine per 3 to 10 ×106 cells resulting in high 
labeling efficiency.105 upon intravenous injection of ap-
proximately 800 ×106 labeled cells, only 1 lesion in 15 
patients was visualized. Similar findings have been re-
ported in other clinical studies with comparable culture 
protocols.106, 107 detailed phenotyping of the cells after 
ex-vivo culture revealed a granulocyte-like phenotype 
with expression of cd66, as well as cd14. This might 
suggest that, although radiolabeling has no effect on mac-
rophage viability and function, the ex-vivo culture condi-
tion are of major influence on the homing characteristics 
of monocyte-derived cells.
The in-vivo distribution of ex-vivo macrophage activated 
killer (MAK) cells has been studied with in-vivo labeling 
with 111in-oxine and 18FFDG and linking these cells to the 
bi-specific antibody MDX-H210.108 radiolabeled MaK 
cells were delivered either by iV or intraperitoneal (iP) in-
jection in ten patients with peritoneal relapse of epithelial 
ovarian carcinoma. following 8 of 16 iV infusions or 4 of 
6 IP infusions the labeled cells were tracked to the tumor le-
sions. However, the leakage of 18f-fdg limited the ability 
to confidently confirm the tracking of the MAK cells to the 
tumor in all cases. The addition of MDX-H210 bi-specific 
antibody did not alter the distribution of the cells to tumor 
sites, but accelerated the clearance of iV administered 
MaK cells from the pulmonary circulation.108
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tumor. however, TaMs only partially contributed 
to the overall TSPo expression, and TSPo expres-
sion in TaMs did not correlate with PeT imaging. 
To the contrary, high TSPo expression was mea-
sured in 20/25 (80%) of the patient-derived breast 
cancer xenografts.123 immunohistochemistry showed 
that a significant portion of the tumor stromal TSPO 
expression co-localized with f4/80 positive macro-
phages cells. 18F-N-(2-(2-fluoroethoxy)benzyl)-N-(4-
phenoxypyridin-3-yl)acetamide (18f-fePPa). Tumor 
uptake of 18f-fePPa in mice bearing subcutaneous 
Mda-MB-231 breast cancer xenografts was evaluat-
ed by PeT imaging and ex-vivo biodistribution stud-
ies. although the tumor was successfully visualized, 
ex-vivo biodistribution studies revealed low tumor 
uptake (0.7%ID/g), with the majority of radioactiv-
ity distributed in the spleen, muscle, and heart de-
spite high TSPo expression in this cell line.124 To our 
knowledge, no clinical studies on imaging of TAMs 
by targeting TSPo have been reported.
Active uptake via endocytic pathways
cell labeling using ldl
radiolabeled rhdl nanoparticles loaded with 89Zr 
have been evaluated in an orthotopic mouse model of 
breast cancer to specifically image TAMs. Two variants 
of the nanoparticles were investigated; phospholipid- 
and apoa-i-labeled rhdl and both probes resulted in 
high tumor accumulation (16.5±2.8 and 8.6±1.3 %ID/g, 
respectively) at 24 hours after injection. histologic 
analysis demonstrated good co-localization of radioac-
tivity with TaM-rich areas in tumor sections. further-
more, flow cytometry analyses showed high uptake of 
rhdl nanoparticles per cell (6.8-fold higher in TaMs 
than in tumor cells for both nanoparticles) and account-
ed for nearly 50% of the total accumulated activity in 
the tumor lesion.125
cell labeling using nanoParticles
Macrophages display a wide array of means for en-
gulfing particles from the microenvironment, including 
phagocytosis, endocytosis and pinocytosis. for imaging 
purposes, nanoparticles have experienced great interest 
in the recent years, as nanoparticles can be modulated 
to optimize tissue distribution (size, charge, coating) 
populations yield conflicting results,117, 118 perhaps indi-
cating that the pan-macrophage marker CD68 does not 
sufficiently reflect the functional orientation of TAMs 
in cancer.
interesting approaches, that use pharmacological 
editing of cellular metabolism to increase the differ-
ence in glycolysis in tumor cells versus TaMs, have 
recently been reported. The peroxisome proliferator-
activated receptor-gamma (PPARγ), member of the 
nuclear receptor superfamily of ligand-dependent 
transcription factors, has been shown to have an anti-
inflammatory effect. The PPARγ agonist pioglitazone 
was studied in a macrophage cell line (raW264.7) 
and three tumor cell lines (a549, KB, and Mda-
MB-231). after treatment with pioglitazone, the up-
take of 18f-fdg in the macrophages was decreased 
and uptake of 18f-fdg in the tumor cells was in-
creased. Unlike tumors, the RAW264.7 xenograft 
model showed the reduced 18F-FDG uptake in the 
inflammatory lesion from 11.74±1.19 to 6.50±1.47 
(%id/g). The increase in 18f-fdg in the different 
tumor cell lines was less profound.119 Similar find-
ings are reported for rosiglitazone.120 in preclinical 
models on atherosclerosis, intravenous injections of 
gM-cSf increased detection by 18f-fdg PeT, by 
augmenting the glycolytic flux within inflamed ath-
eroma in vivo, demonstrating that gM-cSf can be 
used to enhance detection of inflammation.121
cell labeling using tsPo
originally discovered as peripheral benzodiazepine 
receptor in cells of the central nervous system, with 
high affinity binding of diazepam, this mitochondri-
al receptor was renamed to “translocator protein-18 
kDa” (TSPO). The most studied function of TSPO is 
in steroid synthesis through regulation of cholesterol 
transport from the outer to the inner mitochondrial 
membranes, especially in activated microglial cells 
and macrophages. as such it is a target for PeT im-
aging of neuroinflammation using isoquinoline car-
boxamide derivative R-[N-methyl-11cPK-11195 as 
prototype tracer. in twenty-two patients with glioma, 
dynamic 11c-(r)PK11195 imaging was performed.122 
Tracer binding potential in high-grade gliomas was 
significantly higher than in low-grade astrocytomas, 
and correlated with the expression of TSPo in the 
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Active uptake via specific receptors
cell labeling targeting the mannose recePtor
along with the highly diverse and plastic phenotype 
of TaMs, heterogeneity in intratumoral niches imply 
differentially orientated TAMs that express specific re-
ceptors. Pro-angiogenic TaMs that reside in hypoxic 
tumor areas for example express macrophage mannose 
receptor (MMr, cd206). This receptor can be targeted 
with nanobodies, which are single-domain antigen-
binding fragments derived from Camelidae heavy-chain 
antibodies. MMR-specific nanobodies stained TAMs in 
lung and breast tumor single-cell suspensions in vitro. 
in a preclinical model, intravenous injection of 99mTc-
labeled anti-MMr nanobodies successfully targeted 
tumor in vivo. retention of the nanobody was receptor-
specific and absent in MMR-deficient mice. To enhance 
signal-to-background ratios, co-injection of unlabeled 
anti-MMR nanobodies reduced to background uptake 
in normal organs, without compromising tumor uptake. 
further, anti-MMr nanobodies accumulated in hypoxic 
regions, thus supporting the hypothesis that pro-angio-
genic TaMs were targeted.132 following the same prin-
ciple, a PeT tracer 18F-fluorobenzoate (FB)-anti-MMR 
nanobody was developed using the prosthetic group 
n-succinimidyl-4-18F-fluorobenzoate (18f-SfB). The 
kidney retention of the fluorinated nanobody was 20-
fold lower than a 99mTc-labeled counterpart. compared 
with MMR- and CCR2-deficient mice, significantly 
higher uptake was observed in tumors grown in wild-
type mice.133
Conclusion and future directions
In-vivo imaging faces the challenge to image specific 
subsets of immune cells, which are present only in small 
absolute numbers in cancer lesions and display a highly 
dynamic behavior. The contemporary imaging toolbox 
for researchers, as well as clinicians, provides a diverse 
range of possible imaging modalities and tracers. The 
most optimal combination of radionuclide/contrast 
agent, tracer and thus imaging modality highly depends 
on the hypothesis and involved immune cell population 
under question. This review aimed to provide arguments 
that can guide the design of an in-vivo imaging study on 
tumor-infiltrating immune cells in both preclinical and 
clinical setting.
or cellular distribution (coating, targeting moieties), 
and can be loaded with a variety of (multimodal) con-
trast agents.126 As such, nanoparticles provide efficient 
scaffolds for in-vivo or ex-vivo labeling of macro-
phages.38, 39, 74
for example, Plga-based nanoparticles of 200 nm 
in size can be loaded with 19F, as well as different fluo-
rescent dyes for tracking even relatively non-phagocytic 
dendritic cells: human myeloid and plasmacytoid den-
dritic cells. Using these different fluorescence labels, 
simultaneous imaging of distinct immune cell popula-
tions is feasible on a clinical 3T Mr scanner with rea-
sonable acquisition times. The estimated sensitivity was 
2 million cells/MrS voxel for non-phagocytic cells and 
200,000 cells for highly phagocytic cells, e.g. mono-
cyte-derived dendritic cells, which would be sufficient 
for clinical studies.127
including a radionuclide for PeT imaging would po-
tentially improve the sensitivity of detecting nanoparti-
cle-labeled TaMs to allow whole body imaging.128, 129 
Cross-linked dextran nanoparticles, of 13 nm in size, 
have been labeled with 89Zr and injected iV in a cT26 
mouse tumor model to target TaMs.130 Phenotyping 
the in-vivo labeled TaM populations isolated from the 
tumor revealed a rather unspecific targeting of popula-
tions of ly6chi, ly6clo and f4/80hi cells. however, tu-
mors could successfully be visualized with <5% of the 
injected dose needed for Mr imaging.
cell labeling using (u)sPio
(u)SPio nanoparticles are clinically approved for 
lymph node staging on MR, based on the uptake of 
particles that have diffused into the interstitial space by 
phagocytic myeloid cells.129 in a series of experiments, 
Daldrup-Link et al. compared the clinical compound 
with optimized SPios for imaging TaMs. f4/80+ mouse 
macrophages were labeled ex vivo with ferumoxytol, a 
dextran coated 30-nm nanoparticle; P904, a hydrophil-
ic-coated 21-nm nanoparticle, or P1133, a hydrophilic 
coated plus folate 26-nm nanoparticle.131 They showed 
improved uptake ex vivo and increased change in r2 
signal on Mr imaging with folate coated nanoparticles 
at 24 hours post-injection, suggesting that modifications 
of the coating can optimize cellular uptake of nanopar-
ticles.
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ous types of cancer, and patients with high expression of 
PDL-1 are most likely to benefit from this therapy. Hes-
kamp et al. developed an 111in-labeled anti-Pdl-1 anti-
body with accumulation in Pd-l1 expressing tumors and 
no specific uptake was observed in tumors with low or no 
detectable levels of Pd-l1. Moreover, SPecT/cT and 
autoradiography showed a heterogeneous distribution 
of 111in-Pd-l1 within the tumor, which might be worth-
while to explore in future studies. The recent development 
on “small engineered protein” radiotracers highlights the 
current interest in imaging human immune checkpoints.
Advanced image analysis
heterogeneity within cancer lesions has long been 
recognized from clinical images, however accurate 
measures to interpret particular patterns were lacking. 
intra-tumoral heterogeneity plays an important role in 
immune cell imaging, since the infiltration of immune 
cell populations can be very heterogeneously distrib-
uted within the tumor, which potentially hints on their 
role in the microenvironment. improved algorithms to 
classify regions of tumor tissue and to extract as much 
data from both PeT and Mr scan images are now open-
ing up avenues for validation in clinical settings. In-vivo 
defining the metabolic and functional profiles of tumors 
on molecular, cellular and tissue level has the poten-
tial to consolidate imaging technology as most valuable 
tool in the field of cancer treatment.
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recent developments, mentioned below, are foreseen 
to play a critical role in the optimization and individual-
ization of anti-cancer therapy in the near future.
Multimodal imaging
it would be simplistic to expect that the complex in-
teractions of both tissue resident stromal and recruited 
immune cells with the heterogeneous population of 
cancer cells can be evaluated by assessing a single pa-
rameter. The stringent requirements for an imaging ap-
proach to evaluate tumor-infiltrating immune cells can 
currently only be met exploiting multiple modalities. 
dce and dW Mr imaging is increasingly being used 
to evaluate tissue changes to therapy at ultra-high reso-
lution, it allows measures of plasma volume fraction/
micro vessel density (fpV), vessel permeability (Ktrans 
and kep), cellularity (apparent diffusion coefficient). The 
inflammatory responses elicited by anti-cancer therapy 
are known to induce these changes, prior to shrinkage 
of tumor volumes, which could help to characterize 
changes in cellular composition of TMe following anti-
cancer therapy, in particular in combination with meta-
bolic evaluation of cancer lesions with 18f-fdg PeT.
Antibody fragments, peptides and small molecules
Considering the high specificity of radiolabeled 
mAbs, effort have been made to increase the specific 
targeting of immune cells by using smaller antibody 
fragments, like “minibodies,” “diabodies” or scFv’s, 
peptides and small molecules which have a more rapid 
tissue penetration, rapid clearance and generally reveal 
higher target-to-background ratios. Together with us-
ing PeT radionuclides such as 18f or 68ga, these agents 
could improve image quality to clinically relevant lev-
els, which will boost in-vivo imaging. To this end, care-
ful evaluation of possible effect of tracers on labeled 
immune cells, in particular labeling-induced exhaustion 
and interactions with other cells in the TMe, is urgent.
Selecting therapeutic targets
Radiolabeled mAbs targeting disease-specific pro-
cesses are likely to have increasing impact on treatment 
stratification. For example, antibodies blocking the 
Pd1-Pdl-1 axis have shown impressive results in vari-
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